CAH stock forecast, quote, news & analysis

Key Takeaways

• Cardinal Health (CAH) shares rose about 12.8% over the last 30 days, from a closing price of $225.38 to an intraday level near $254.20, pushing the stock back toward 52-week highs.
• The rally followed a binding letter of intent with CVS Health to extend a major pharmaceutical distribution agreement until June 2032.
• A series of analyst price-target increases, plus a ratings upgrade, reinforced bullish sentiment during the period.
• Strong fiscal 2026 results and fiscal 2027 guidance projecting 13%–15% non-GAAP EPS growth underpin the company's fundamental momentum.
• Over the last quarter the advance has been more volatile, with a late-September pullback into the low $220s before the October rebound.

Cardinal Health (CAH) Company Overview and Market Position

Cardinal Health, Inc. is a global healthcare services and products company and one of the three largest U.S. pharmaceutical distributors, alongside Cencora (COR) and McKesson (MCK). Its Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals and specialty products to pharmacies, hospitals, and other providers. The company also distributes and manufactures medical, surgical, and laboratory products, and operates growth businesses including at-Home Solutions, OptiFreight Logistics, and Nuclear and Precision Health Solutions.

Cardinal Health's scale, entrenched distribution relationships, and expanding specialty and high-growth segments such as theranostics and cell-and-gene therapy logistics make it a closely followed name among healthcare investors. Its recurring revenue model and steady free cash flow support an active share-repurchase and dividend program.

Cardinal Health (CAH) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, CAH climbed roughly 12.8%, advancing from a closing price of $225.38 on September 18 to an intraday level near $254.20, approaching its 52-week high. The move accelerated in October, with the stock rising from around $222–$230 at the start of the month to the mid-$250s by mid-month.

The last quarter tells a more uneven story. From mid-July levels near $226, the stock is up roughly 12%–13% on a net basis, but the path was far from linear. Shares pulled back into the $216–$221 range in late September before the October catalysts sparked a sharp recovery. The quarterly trend therefore reflects a consolidation and brief drawdown followed by a strong, catalyst-driven rebound rather than a straight-line advance.

What Drove CAH Stock Price in the Last 30 Days

The most significant recent catalyst came on October 1, when Cardinal Health announced it had signed a binding letter of intent with CVS Health (CVS) to extend its pharmaceutical distribution agreement until June 2032. The agreement maintains Cardinal Health's existing distribution services for CVS Health, removing a key contractual uncertainty, and the company reaffirmed its fiscal 2027 adjusted EPS growth target of 13%–15% ($12.40–$12.60). Shares rose sharply on the news.

Positive analyst activity reinforced the move. Evercore ISI raised its price target to $270 from $265, RBC Capital maintained a Buy rating with a $276 target, UBS lifted its target to $295 from $280, and Mizuho boosted its target to $280 from $250. Separately, Weiss Ratings upgraded the stock in early October. The company's quarterly dividend of $0.5158 per share was also paid on October 15, reflecting continued shareholder returns.

What Drove CAH Stock Performance Over the Last Quarter

The broader multi-month trend has been shaped by strong operational execution rather than any single event. In August, Cardinal Health reported fiscal 2026 revenue of $254.2 billion, up 14%, and non-GAAP diluted EPS of $11.26, up 37%, while introducing fiscal 2027 guidance of $12.40–$12.60 per share. The company also expanded its share-repurchase authorization by $5 billion, signaling confidence in sustained earnings growth.

Growth in specialty distribution, GLP-1 demand, and higher-margin businesses such as nuclear and precision health and at-Home Solutions has supported the narrative, even as tariff-related effects and drug-pricing dynamics created some quarter-to-quarter noise in the medical products segment. The late-September dip reflected broader market consolidation, after which the CVS agreement extension and analyst upgrades reignited buying interest.

Trending AI Robots

For traders seeking a data-driven edge, Tickeron's Trending AI Robots page highlights a curated selection of the platform's top-performing AI trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the most relevant and highest-performing bots are featured in this section. These bots vary widely in strategy, trading timeframe, and performance metrics, allowing users to explore approaches ranging from short-term momentum to longer-horizon trend following. Reviewing the Trending AI Robots section can help investors identify automated strategies that align with their own objectives and risk tolerance.

CAH Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors should monitor Cardinal Health's next quarterly earnings report and any updates to fiscal 2027 guidance, which currently calls for 13%–15% non-GAAP EPS growth. The finalization of the CVS Health distribution extension, execution across specialty and GLP-1-related volumes, and progress in higher-growth segments such as theranostics and cell-and-gene therapy logistics remain important themes. Drug-pricing changes tied to the Inflation Reduction Act, tariff developments affecting the medical products business, and broader healthcare-policy dynamics could also influence results. Competitive pressure from Cencora and McKesson, along with valuation considerations after the recent run, are additional factors worth tracking.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations